Published in Semin Nucl Med on September 01, 2008
Cancer radioimmunotherapy. Immunotherapy (2011) 1.10
Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'. Yale J Biol Med (2011) 1.04
Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization. Theranostics (2016) 0.96
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics (2015) 0.94
Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer. PLoS One (2013) 0.86
Microdosimetry for targeted alpha therapy of cancer. Comput Math Methods Med (2012) 0.83
Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med (2013) 0.82
(S)-5-(p-nitrobenzyl)-PCTA, a promising bifunctional ligand with advantageous metal ion complexation kinetics. Bioconjug Chem (2009) 0.81
Analysis of the contribution of charge transport in iodine-125-induced DNA damage. Radiat Res (2010) 0.78
Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models. PLoS One (2015) 0.77
Standards and Methodologies for Characterizing Radiobiological Impact of High-Z Nanoparticles. Theranostics (2016) 0.77
α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation. J Nucl Med (2015) 0.76
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol (2017) 0.75
Highly Effective Auger-Electron Therapy in an Orthotopic Glioblastoma Xenograft Model using Convection-Enhanced Delivery. Theranostics (2016) 0.75
Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody. Oncotarget (2016) 0.75
In-Situ Formation of Holmium Oxide in Pores of Mesoporous Carbon Nanoparticles as Substrates for Neutron-Activatable Radiotherapeutics. Carbon N Y (2017) 0.75
Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha -particle irradiated to nonirradiated cells. Proc Natl Acad Sci U S A (2001) 2.74
Tumor therapy with targeted atomic nanogenerators. Science (2001) 2.48
Alpha particles initiate biological production of superoxide anions and hydrogen peroxide in human cells. Cancer Res (1997) 2.35
Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J Nucl Med (2006) 2.10
Factors underlying the cell growth-related bystander responses to alpha particles. Cancer Res (2000) 2.00
Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med (1990) 1.97
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res (2000) 1.85
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A (2000) 1.81
Absorption of 20-eV to 50,000-eV electron beams in air and plastic. Radiat Res (1969) 1.49
Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet (1998) 1.34
Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science (1988) 1.32
Alpha particles induce the production of interleukin-8 by human cells. Radiat Res (1999) 1.30
Kinetics of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res (1987) 1.25
(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med (2007) 1.25
Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci U S A (2002) 1.21
The amazing world of auger electrons. Int J Radiat Biol (2005) 1.21
Radiotoxicity of 125I in mammalian cells. Radiat Res (1987) 1.11
Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med (1994) 1.10
The radiotoxicity of iodine-125 in mammalian cells II. A comparative study on cell survival and cytogenetic responses to 125IUdR, 131TUdR, and 3HTdR. Radiat Res (1976) 1.06
Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res (2001) 1.04
Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res (1994) 1.02
Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat Res (1982) 1.01
Therapeutic potential of 5-[125I]iodo-2'-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. Int J Radiat Biol (2005) 0.97
5-125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature (1977) 0.96
Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol (1999) 0.95
Astatine-211--tellurium radiocolloid cures experimental malignant ascites. Science (1981) 0.95
MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med (2007) 0.94
The in vitro radiobiology of astatine-211 decay. Radiat Res (1986) 0.92
Radiotoxicity of 75Se and 35S: theory and application to a cellular model. Radiat Res (1980) 0.90
5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys (1991) 0.88
Inhibitory and stimulatory bystander effects are differentially induced by Iodine-125 and Iodine-123. Radiat Res (2006) 0.87
Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat Res (1998) 0.86
Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs. Eur J Cancer Clin Oncol (1987) 0.84
Cytotoxicity of [125I]iodoHoechst 33342: contribution of scavengeable effects. Int J Radiat Biol (1999) 0.84
The impact of tumor cell proliferation in radioimmunotherapy. Cancer (1994) 0.81
Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer. Acta Oncol (1996) 0.81
123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines. J Nucl Med (2007) 0.79
Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2. Cancer (1997) 0.78
Does nonuniformity of dose have implications for radiation protection? J Nucl Med (1992) 0.77
Iodine-125-labelled tamoxifen is differentially cytoxic to cells containing oestrogen receptors. Int J Radiat Biol Relat Stud Phys Chem Med (1980) 0.77
Molecular suicide studies of 125I and 3H disintegration in the DNA of Chinese hamster cells. Curr Top Radiat Res Q (1978) 0.77
Radiobiologic principles in radionuclide therapy. J Nucl Med (2005) 1.23
In vivo validation of the bystander effect. Hum Exp Toxicol (2004) 0.76